SCHEDULE 13G/A: The Hewlett Fund LP Divests Entire Stake in Plus Therapeutics, Reports Zero Beneficial Ownership

The Hewlett Fund LP has filed an amended Schedule 13G, reporting zero beneficial ownership of common stock in Plus Therapeutics, Inc., indicating a complete divestment of its previous holdings.

Summary

• The Hewlett Fund LP filed an Amendment No. 1 to Schedule 13G concerning its beneficial ownership of common stock in PLUS THERAPEUTICS, INC.
• The filing indicates that The Hewlett Fund LP now holds 0 shares, representing 0% of the class of securities.
• This amendment signifies a complete divestment of their previous beneficial ownership in Plus Therapeutics, Inc.
• The CUSIP number for the securities is 72941H509, and the par value per share is $0.001.
• The event requiring this filing occurred on June 24, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the complete divestment by an institutional investor, which could be interpreted by the market as a lack of confidence, even though the filing itself is a neutral disclosure of fact.

Positives

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of Plus Therapeutics, Inc., which can reassure current management and other investors about the fund's intentions.

Negatives

• The Hewlett Fund LP has divested its entire beneficial ownership in Plus Therapeutics, Inc., reducing its stake from a previously reportable amount to 0%.
• A significant institutional investor reducing its stake to zero could be perceived negatively by the market, potentially signaling a lack of confidence in the company's future prospects or a shift in the fund's investment strategy.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing is a routine regulatory disclosure of a change in institutional ownership. It reflects a specific investment decision by The Hewlett Fund LP regarding Plus Therapeutics, Inc., rather than a broader industry trend. However, significant institutional divestments can sometimes precede or coincide with shifts in investor sentiment within a particular sector.

Stakeholder Impact

• Shareholders: Existing shareholders of Plus Therapeutics, Inc. may view the complete divestment by The Hewlett Fund LP as a negative signal, potentially leading to increased selling pressure or a re-evaluation of the company's investment attractiveness.
• Management: Management of Plus Therapeutics, Inc. might need to address investor concerns arising from the divestment, though the filing explicitly states the fund's holdings were not for control purposes.

Key Dates

Keywords

Plus Therapeutics, The Hewlett Fund LP, Schedule 13G, beneficial ownership, common stock, divestment, institutional investor, SEC filing, ownership change